Tatsuaki Morokata, Ph.D.

President, Astellas Innovation Management LLC

 
 
 


Dr. Tatsuaki Morokata joined Astellas in 1995 (formerly Yamanouchi Pharmaceutical Co. Ltd.), and he currently manages Astellas Innovation Management LLC which are responsible for acquiring internal and external innovation opportunities in the preclinical development stage, including strategy planning, screening, scientific, assessment and alliance negotiations.

His other professional and managerial experience at Astellas include the following: Divisional Senior Vice President, Innovation & Incubation Research Labs and President, Astellas Innovation Management LLC (2018- March 2019); Executive Director, New Product Science Strategy Group, Product and Portfolio Strategy (2017-2018); Executive Director, ImmunoScience Research Unit, Research and Portfolio Science (2014-2016); Senior Director, Innovation Research Lab, Molecular Medicine Research Labs (2012-2013). Post Doctorial Research Fellow at Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School (2009 to 2010).

Dr. Morokata has more than 25 years of experience in immunology research from early to late stage drug discovery.
He received his Ph.D. in Pharmaceutical Science from the University of Tokyo.   

 

 

michael.jpg

 Michael Luther Ph.D., MBA

Head of North America Scouting

 
 
 


Dr. Michael Luther is the Head of North American Scouting, AIM.  Mike brings over 33 years’ experience as an entrepreneurial scientist and executive in the biopharmaceutical industry.

Before joining Astellas full-time, Mike was a consultant to Mitobridge, and was also the founding CEO of Bantam Pharmaceutical, a biotech company focused on developing novel therapeutics in cancer metabolism.  

In past roles, Mike was the Senior Vice President for Drug Discovery & Development at Albany Molecular Research (AMRI), and founding President of the North Carolina Research Campus.

Mike has over 20 years in executive roles in the global pharmaceutical industry including Vice President and head of R&D for Merck-Canada in Montreal, and Vice President of Drug Discovery at GlaxoSmithKline.  In 16 years at GSK, he led multiple discovery teams and organizations including GSK-Japan that resulted in the successful launch of 4 new therapeutics in oncology and metabolic disease as well as initiating the pharmaceutical industry’s first efforts in precision medicine and drug repositioning. 

Dr. Luther holds Bachelor of Science degrees from North Carolina State University, a doctorate degree from St. Louis University School of Medicine, and an MBA from Duke University.  He was a Carl Stone Muscular Dystrophy Fellow at The Salk Institute, and is the author of over 67 publications and holds issued patents for diagnostics and pharmaceuticals.

 

 

image

 Bradley Hardiman

Head of Europe Scouting

 
 
 


Bradley Hardiman is the Head of Europe Scouting, AIM and is based in Cambridge UK.

A biochemist by training, Bradley started his career working for the world’s largest pharmaceutical companies. He has spent the last 20 years commercialising research through collaborations, licensing and venture capital investing.

In a previous role, Bradley worked within the seed funds team at Cambridge Enterprise, where he helped create and invest in spin-outs founded on University of Cambridge research. These companies have gone on to raise additional capital to help develop their technologies.

Bradley joined Astellas in April 2021. However his path has crossed with the organisation before. He was an early investor in Quethera, which was acquired by Astellas in 2018. He also invested in Phoremost, which Astellas invested in, in 2021.

 

 

Kazunori Inabe, Ph.D., MBA

Head of Partnering process Management

 

 


Dr. Inabe is the Head of Partnering Process Management based in Brisbane, CA, since April 2020. He most recently served as Senior Director at Innovation Management based in Japan. There, he led a Japan-based team responsible for transaction and alliance management of projects in early-stage partnerships with biotech companies or academic institutions. In this role, he was involved in partnerships with nearly 20 biotech companies or academic institutions, such as Mitobridge, Inc., Proteostasis Therapeutics, and Harvard Medical School. He also served as a member of the Joint Steering Committee or Alliance Manager for the partnerships with Cytokinetics, Inc., Mitobridge, Inc. and Potenza Therapeutics, Inc.  

From 2009 to 2011, Dr. Inabe was a member of Astellas Venture Management LLC, a US-based corporate venture capital arm of Astellas Pharma, that is engaged in strategic investment activities in the biotech industry. Prior to joining Yamanouchi, the former company of Astellas, in 2002, Dr. Inabe’s career in life sciences included work as an Assistant Professor at Kansai Medical University, Osaka, Japan. He holds a Ph.D. in Medical Science from Hokkaido University and an M. B. A. from Globis University. 

 

 

shindo.jpg

Nobuaki Shindoh, Ph.D.

Head of Research Partnering Operations

 

 


Dr. Shindoh is the Head of Research Partnering Operations at Innovation Management, Astellas Pharma Inc.  He currently manages a Japan/US-based team responsible for alliance management and the administration of early-stage partnering projects with academic institutions and biotech companies.

Prior to this role, he was the Scouting and Science Lead for innovative opportunities in the oncology field at Astellas Innovation Management LLC and engaged in building partnerships with US/EU based institutes and biotech companies such as MD Anderson Cancer Center, Dana-Farber Cancer Institute and Cancer Research UK.  From 2014 to 2016, he was a member of Astellas Venture Management LLC, a corporate venture capital arm of Astellas where he was engaged in strategic investments and monitored several private early-stage companies.

He has over 20 years of professional experience in oncology research involving early to late-stage drug discovery. During this period, he has engaged in over 20 drug discovery research programs including a leukemia drug program, gilteritinib/XOSPATA®, which is currently on the market.

 

Tomoya Oe, Ph.D.

Senior Manager
Boston Office

 

Tomohiro Yoshida

Senior Manager
Boston Office

 

Akira Okajima

Manager
Boston Office

 

 
Shingo Yamasaki,Ph.D.

Senior Manager
San Francisco Office

 

Shinichi Miyake, Ph.D.

Senior Manager
San Francisco Office

 

Munemichi, Ohe, Ph.D.

Manager
San Francisco Office

 

 
Minoru Kameda, Ph.D.

Associate Director
Japan Office

 

Takeshi Hondo, Ph.D.

Senior Manager
Japan Office

 

Hiroyuki Usuda, Ph.D.

Manager
Japan Office

 

 
Fumihiro Nakamori, Ph.D., MBA

Manager
Japan Office

 

Nuno Alves Ph.D.

Associate Director
Cambridge UK Office